J Transl Genet Genom 2021;5:[Accepted].10.20517/jtgg.2021.34@The Author(s) 2021
The effect of HMGB1 and RAGE on the clinicopathological and prognostic features of prostate cancer
Correspondence Address: Prof. Dao-Jun Lv, Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, Guangdong, China. E-mail: email@example.com
Received: 7 Jul 2021 | Revised: 6 Sep 2021 | Accepted: 9 Sep 2021 | First online: 11 Sep 2021
AbstractAs a DNA-binding protein, high mobility group box 1 (HMGB1) has been shown be involved in various biological activities, including transcription regulation, DNA repair, genomic stability, and extracellular signaling. Accumulating evidence indicates that HMGB1 has an important role in biological processes in cancer. Moreover, HMGB1 has been shown to have intracellular and extracellular roles, activating key cancerogenic signaling pathways. The main signal pathway is activated via the interaction of HMGB1 with its receptor, receptor for advanced glycation end-products (RAGE). In addition, overexpression of HMGB1/RAGE occurs in certain types of primary tumors and has been linked to increased metastasis and poorer prognosis. In our previous research, we demonstrated that co-expression of HMGB1 and RAGE is associated with cancer progression and poor patient outcome in prostate cancer (PCa). Together with the recent published evidence, we describe and speculate on the character of the HMGB1/RAGE axis in PCa progression and elaborate on future prospects for the application of potential strategies to target HMGB1 in PCa therapy.
KeywordsHigh mobility group box 1, receptor for advanced glycation end-products, prostate cancer
Cite This Article
Lv DJ. The effect of HMGB1 and RAGE on the clinicopathological and prognostic features of prostate cancer. J Transl Genet Genom 2021;5:[Accept]. http://dx.doi.org/10.20517/jtgg.2021.34